Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Jan 21, 2010

Premium

Bar Harbor BioTechnology this week released its XenoQ assays, which are designed to quantitatate human tumor response in xenograft experiments.

The assays combine quantitative PCR primer design with Bar Harbor's Global Pattern Recognition-analysis methodology, which allows researchers to "accurately measure gene expression and gene copy number variation in human cancer cells without cross-reactivity of other species," the company said in a statement.

Researchers can use the assays to measure how a drug affects a tumor and detect if there is a correlation of dosage to gene copy-number variations found in a patient's cells, the company said.

Bar Harbor has signed an agreement with Lonza to distribute the XenoQ assays. The deal expands a distribution agreement between the firms that began in 2008 that made Lonza the exclusive global distributor of the company's StellArray Gene Expression System, which combines qPCR arrays with the GPR software.

In addition to XenoQ, Lonza will now distribute Bar Harbor's GPR 2.0 and Custom Plate Designer products under the expanded agreement.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.